Working with, ErVaccine Technologies, a preclinical-stage biotechnology company, Complete Omics scientists utilized our multi-omics companion diagnostics platform to help enable next-generation therapeutic vaccines and cellular immunotherapies targeting so-called “unconventional” tumor antigens, such as those derived from HERVs. These antigens are shared by different tumor types. Their use would provide a therapeutic solution for a larger number of patients.
This scientific publication outlines results which make it possible to consider triple-negative breast cancer as a first indication, and then to target other pathologies such as ovarian cancer, sarcoma, glioblastoma and acute myeloblastic leukemia as subsequent indications [Ref 1].
“We are very happy to work together with Stéphane and his team on developing this new class of cancer therapeutic targets further into clinical utilizations. Companion diagnostics is a very important multi-omics branch that Complete Omics is working on. We are working together with our collaborators from pharmaceuticals, biotechs, and research institutions to couple our patented multi-omics companion diagnostics platforms with their actionable therapeutic strategies.” explains Dr. Qing Wang, Founder of Complete Omics Inc.
Complete Omics Inc. is specialized in developing multi-omics molecular diagnostics tests for a variety of human diseases and developing companion diagnostic solutions for patients and pharmaceutical companies. Other than our own research, we are also working with dozens of institutional collaborators on a variety of different novel applications using our world-leading multi-omics platforms. A lot more milestones are expected to come true soon in 2022. Stay Tuned.
